Gene targets with therapeutic potential in hepatocellular carcinoma  

作　　者：Syifaus Shodry Yuliono Trika Nur Hasan Iwal Reza Ahdi Zulvikar Syambani Ulhaq 

机构地区：[1]Faculty of Medicine and Health Sciences,Maulana Ibrahim Islamic State University of Malang,Malang 65144,Jawa Timur,Indonesia [2]Research Center for Preclinical and Clinical Medicine,National Research and Innovation Agency Republic of Indonesia,Cibinong 16911,Indonesia

出　　处：《World Journal of Gastrointestinal Oncology》2024年第12期4543-4547,共5页世界胃肠肿瘤学杂志（英文）

摘　　要：Hepatocellular carcinoma(HCC)is the third leading cause of cancer-related deaths worldwide.Major treatments include liver transplantation,resection,and chemotherapy,but the 5-year recurrence rate remains high.Late diagnosis often prevents surgical intervention,contributing to poor patient survival rates.Carcinogenesis in HCC involves genetic alterations that drive the transformation of normal cells into malignant ones.Enhancer of zeste homolog 2(EZH2),a key regulator of cell cycle progression,is frequently upregulated in HCC and is associated with advanced stages and poor prognosis,making it a potential biomarker.Additionally,signal transducer and activator of transcription 3,which binds to EZH2,affects disease staging and outcomes.Targeting EZH2 presents a promising therapeutic strategy.On the other hand,abnormal lipid metabolism is a hallmark of HCC and impacts prognosis.Fatty acid binding protein 5 is highly expressed in HCC tissues and correlates with key oncogenes,suggesting its potential as a biomarker.Other genes such as guanine monophosphate synthase,cell division cycle associated 5,and epidermal growth factor receptor provide insights into the molecular mechanisms of HCC,offering potential as biomarkers and therapeutic targets.

关 键 词：Hepatocellular carcinoma Enhancer of zeste homolog 2 Target genes Biomarkers Potential therapeutic 

分 类 号：R735.7[医药卫生—肿瘤]